Molecular Tumor Board at the Center for Personalized Medicine Tübingen

Launched by UNIVERSITY HOSPITAL TUEBINGEN · Apr 18, 2018

Keywords

ClinConnect Summary

The "Molecular Tumor Board at the Center for Personalized Medicine Tübingen" is a clinical trial focused on helping patients with advanced cancer. This trial is designed to assist doctors in understanding the specific characteristics of a patient's tumor by analyzing its genetic makeup. By doing this, the team can suggest personalized treatment options that may be more effective for each individual.

To participate in this trial, patients need to be at least 18 years old and must have received a recommendation from their treating doctor to be referred to the Molecular Tumor Board. Participants will work closely with a team of experts who will review their tumor's genetic information and help their doctors decide on the best treatment approach. It's important to note that this trial is specifically for cancer patients, and those without a cancer diagnosis will not be eligible to join. If you or a loved one is facing advanced cancer, this trial could provide valuable support in finding the right treatment plan.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Given informed consent ("broad consent" of the University Hospital Tübingen)
• • ≥ 18 years of age
• • Clinical indication for a referral to Molecular Tumor Board by the treating physician
• Exclusion Criteria:
• • The MTB assists the referring physician with the interpretation and the use of tumor molecular profiling data for deciding on a therapeutic strategy. Therefore, this board is confined to cancer patients and cannot provide any service for non-cancer patients